Navigation Links
Questcor to Present at UBS Global Life Sciences Conference
Date:9/20/2010

UNION CITY, Calif., Sept. 20 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) announced today that it will present at the UBS Global Life Sciences Conference on Wednesday, September 22, 2010 at The Grand Hyatt Hotel in New York. Don M. Bailey, President and Chief Executive Officer, will discuss the Company's business strategy and historical financial performance at 3:30 p.m. Eastern Time.

Attendance at this conference is by invitation only. A live audio and slides webcast of Questcor's presentation may be accessed through the Company's website at www.questcor.com. An archived replay of the presentation will be available after the live presentation, and can also be accessed at www.questcor.com.

About Questcor

Questcor Pharmaceuticals is a biopharmaceutical company whose products help patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection). H.P. Acthar Gel ("Acthar") is an injectable drug that is approved for the treatment of certain disorders, including the treatment of exacerbations associated with multiple sclerosis ("MS") and to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that is due to lupus erythamatosus. In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Questcor Reports Solid Fourth Quarter Results
2. Questcor to Discuss Results From FDA Panel Meeting
3. Trading Halted Today in Questcor Pharmaceuticals Common Stock
4. Questcor to Present at the Jefferies 2010 Global Life Sciences Conference
5. Questcor Receives Notification of PDUFA Date Extension to September 11, 2010
6. Mitchell J. Blutt, M.D. Appointed to Questcor Board of Directors
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 5, 2016   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... a Phase 2 clinical study of sotagliflozin, a dual ... with JDRF, the leading global organization funding type 1 ... 2 clinical trial, which randomized a total of 87 ... 400 mg dose of sotagliflozin compared to a placebo ...
(Date:12/5/2016)... -- Sharn Anesthesia Inc. announced today that it has been ... Salter Labs.  The company also received the 2015 Salter ... sales performance. Salter Labs is a leading ... the market gold standard ECO 2 sampling cannulas. ... Parker Flex-Tip® Endotracheal Tube, which is a leading patient ...
(Date:12/5/2016)... , the first HIPAA compliant software collaboration platform for patients, physicians ... Styku, a California -based software and ... real-time 3D body scanning and analysis. Together with its other strategic ... feel their health like never before. ... , , "Bringing ...
Breaking Medicine Technology:
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... teaming up on new songs with prolific Songwriter-Producer Corey “Chorus” Gibson who has ... Rowland, Ciara, Brandy…just to name a few.     https://twitter.com/coreychorus , The sessions ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... As renowned, ... heard the dangers and downsides of patients who do not do their research and ... of cosmetic dermatology is in the midst of a renaissance and every other month ...
(Date:12/5/2016)... ... December 05, 2016 , ... A newly released study ... the reproducibility and accuracy of placing precordial electrodes with little cognitive effort and ... last 60 years, studies have shown that single electrode misplacement is one of ...
(Date:12/4/2016)... , ... December 03, 2016 , ... While James Earl ... serving as host for in a show called "Front Page". One of the forthcoming ... years, breast cancer rates have plummeted in large part due to early detection. Like ...
(Date:12/4/2016)... ... December 04, 2016 , ... Patients who ... now take advantage of a cosmetic procedure known as Carbon Dioxide (C02) ... the appearance of age spots, fine lines, uneven coloration, wrinkles, scarring, skin ...
Breaking Medicine News(10 mins):